237 related articles for article (PubMed ID: 18581209)
1. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Zrieki A; Farinotti R; Buyse M
Pharm Res; 2008 Sep; 25(9):1991-2001. PubMed ID: 18581209
[TBL] [Abstract][Full Text] [Related]
2. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
3. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.
Pagliarulo V; Ancona P; Niso M; Colabufo NA; Contino M; Cormio L; Azzariti A; Pagliarulo A
Mol Cancer; 2013 May; 12():47. PubMed ID: 23705854
[TBL] [Abstract][Full Text] [Related]
4. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Xia W; Zhao T; Lv J; Xu S; Shi J; Wang S; Han X; Sun Y
J Cell Biochem; 2009 Sep; 108(1):181-94. PubMed ID: 19562670
[TBL] [Abstract][Full Text] [Related]
6. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
7. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
8. Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression.
Liu Z; Duan ZJ; Chang JY; Zhang ZF; Chu R; Li YL; Dai KH; Mo GQ; Chang QY
PLoS One; 2014; 9(6):e98560. PubMed ID: 24901713
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
10. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein.
Gonçalves P; Gregório I; Martel F
Am J Physiol Cell Physiol; 2011 Nov; 301(5):C984-94. PubMed ID: 21775706
[TBL] [Abstract][Full Text] [Related]
11. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
13. Combination of 7-
Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
[TBL] [Abstract][Full Text] [Related]
14. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells.
Yue GG; Cheng SW; Yu H; Xu ZS; Lee JK; Hon PM; Lee MY; Kennelly EJ; Deng G; Yeung SK; Cassileth BR; Fung KP; Leung PC; Lau CB
J Med Food; 2012 Mar; 15(3):242-52. PubMed ID: 22181075
[TBL] [Abstract][Full Text] [Related]
15. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo.
Zrieki A; Farinotti R; Buyse M
Eur J Pharmacol; 2010 Jun; 636(1-3):189-97. PubMed ID: 20361960
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
[TBL] [Abstract][Full Text] [Related]
18. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
Zatelli MC; Luchin A; Tagliati F; Leoni S; Piccin D; Bondanelli M; Rossi R; degli Uberti EC
Endocr Relat Cancer; 2007 Dec; 14(4):1029-38. PubMed ID: 18045954
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.
Agarwal S; Hartz AM; Elmquist WF; Bauer B
Curr Pharm Des; 2011; 17(26):2793-802. PubMed ID: 21827403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
